Aclaris Therapeutics ACRS Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Contract Research | $537K+20.7% | —— | —— | —— | $445K-29.9% | |
| Dermatology Therapeutics | $1.46M+44.5% | $795K-90.8% | $2.81M-24.0% | $1.34M-37.6% | $1.01M-42.0% | |
| Research And Development Project Spend by Product | ||||||
| Drug Candidate Ati052 | $3.18M+414% | $3.2M+575% | $1.84M+288% | $1.42M+199% | $619K+30.7% | |
| Drug Candidate Ati2138 | $491K-72.8% | $526K-80.1% | $1.47M+97.2% | $1.12M+48.5% | $1.81M+2,770% | |
| Drug Candidate Ati9494 | $2.23M+228% | —— | —— | —— | $678K+14.9% | |
| Drug Candidate Bosakitug | $3.14M-7.2% | $4.55M+5,990% | $3.06M+3,996% | $2.85M+3,709% | $3.38M+4,427% | |
| Drug Discovery Platform | $1.44M+115% | —— | $2.34M+85.3% | $1.62M+0.9% | $668K-56.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Aclaris Therapeutics break its business down?
- Aclaris Therapeutics (ACRS) reports revenue by product across 2 parts — Contract Research and Dermatology Therapeutics. Each is extracted from the segment footnotes and tracked over time.
- Where does Aclaris Therapeutics's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Aclaris Therapeutics's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
